Course Description:  The Conference on Retroviruses and Opportunistic Infections (CROI) was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research. The best and most consequential original research defines the science at CROI, including research in HIV, hepatitis viruses, SARS-CoV-2, mpox, and other viral infections and their related conditions. In this session, Patricia Fulco, PharmD, BCPS, FASHP, AAHIVP will provide an overview of highlights from this year's CROI. 

Course Objectives:

Upon completion of this program, participants will be able to:

1. Describe the updates to real-world implementation of cabotegravir-rilpivirine injections, resistance and use in persons living with HIV not currently suppressed.
2. Evaluate new antiretrovirals in Phase 2 evaluation including doravirine and islatravir for once-weekly dosing for maintaining viral load suppression.
3. List the recent evaluations to manage concurrent hepatitis B in persons living with HIV and preventative strategies.
4. Provide recent trends in integrase inhibitor use and resistance after global implementation of dolutegravir based regimens.

Speaker:

Patricia Fulco, PharmD, BCPS, FASHP, AAHIVP | VCU Health, Richmond, VA

Intended Audience

Doctors, Pharmacists, Nurse Practitioners, Physician Assistants, Nurses, Social Workers, Case Managers

Contact